NO20005100D0 - Genetisk modifiserte celler og fremgangsmÕter for ekspresjon av rekombinant heparanase og fremgangsmÕter for rensing av samme - Google Patents

Genetisk modifiserte celler og fremgangsmÕter for ekspresjon av rekombinant heparanase og fremgangsmÕter for rensing av samme

Info

Publication number
NO20005100D0
NO20005100D0 NO20005100A NO20005100A NO20005100D0 NO 20005100 D0 NO20005100 D0 NO 20005100D0 NO 20005100 A NO20005100 A NO 20005100A NO 20005100 A NO20005100 A NO 20005100A NO 20005100 D0 NO20005100 D0 NO 20005100D0
Authority
NO
Norway
Prior art keywords
methods
purification
expression
same
genetically modified
Prior art date
Application number
NO20005100A
Other languages
English (en)
Other versions
NO20005100L (no
Inventor
Hanna Ben-Artzi
Maty Ayal-Hershkovitz
Oron Yacoby-Zeevi
Iris Pecker
Yoav Peleg
Yinon Shlomi
Original Assignee
Insight Strategy & Marketing
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insight Strategy & Marketing filed Critical Insight Strategy & Marketing
Publication of NO20005100D0 publication Critical patent/NO20005100D0/no
Publication of NO20005100L publication Critical patent/NO20005100L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01166—Heparanase (3.2.1.166)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, Konjac gum, Locust bean gum or Guar gum
    • G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
NO20005100A 1998-05-01 2000-10-10 Genetisk modifiserte celler og fremgangsmåter for ekspresjon av rekombinant heparanase og fremgangsmåter for rensing av samme NO20005100L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7161898A 1998-05-01 1998-05-01
US09/260,038 US6348344B1 (en) 1997-09-02 1999-03-02 Genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same
PCT/US1999/009256 WO1999057244A1 (en) 1998-05-01 1999-04-29 Genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same

Publications (2)

Publication Number Publication Date
NO20005100D0 true NO20005100D0 (no) 2000-10-10
NO20005100L NO20005100L (no) 2000-12-28

Family

ID=26752433

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005100A NO20005100L (no) 1998-05-01 2000-10-10 Genetisk modifiserte celler og fremgangsmåter for ekspresjon av rekombinant heparanase og fremgangsmåter for rensing av samme

Country Status (7)

Country Link
US (4) US6348344B1 (no)
EP (1) EP1076689A4 (no)
JP (1) JP2002513560A (no)
AU (1) AU768820B2 (no)
CA (1) CA2329142A1 (no)
NO (1) NO20005100L (no)
WO (1) WO1999057244A1 (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010006630A1 (en) * 1997-09-02 2001-07-05 Oron Yacoby-Zeevi Introducing a biological material into a patient
US6177545B1 (en) * 1997-09-02 2001-01-23 Insight Strategy & Marketing Ltd. Heparanase specific molecular probes and their use in research and medical applications
US5968822A (en) 1997-09-02 1999-10-19 Pecker; Iris Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells
US6348344B1 (en) * 1997-09-02 2002-02-19 Insight Strategy & Marketing Ltd. Genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same
US20040213789A1 (en) * 1997-09-02 2004-10-28 Oron Yacoby-Zeevi Heparanase activity neutralizing anti-heparanase monoclonal antibody and other anti-heparanase antibodies
US20030161823A1 (en) * 1998-08-31 2003-08-28 Neta Ilan Therapeutic and cosmetic uses of heparanases
US20020088019A1 (en) * 1997-09-02 2002-07-04 Oron Yacoby-Zeevi Methods of and pharmaceutical compositions for improving implantation of embryos
US6699672B1 (en) 1997-09-02 2004-03-02 Insight Biopharmaceuticals Ltd. Heparanase specific molecular probes and their use research and medical applications
US20030217375A1 (en) * 1998-08-31 2003-11-20 Eyal Zcharia Transgenic animals expressing heparanase and uses thereof
US20020068054A1 (en) * 2000-09-11 2002-06-06 Insight Strategy & Marketing Ltd. And Hadasit Medical Research Services And Development Ltd. Therapeutic and cosmetic uses of heparanases
EP1157118A4 (en) * 1999-03-01 2002-07-17 Insight Strategy & Marketing POLYNUCLEOTID ENCODING A POLYPEPTIDE WITH HEPARANASE ACTIVITY AND ITS EXPRESSION IN GENETICALLY MODIFIED CELLS
JP2005500977A (ja) * 2000-12-19 2005-01-13 インサイト ストラテジー アンド マーケティング リミテッド 細胞移植改良のための細胞外基質分解酵素の使用
US6671189B2 (en) * 2001-11-09 2003-12-30 Minebea Co., Ltd. Power converter having primary and secondary side switches
SE0201234D0 (sv) * 2002-04-24 2002-04-24 Avaris Ab Transfer complex with added functionality and methods for its use
IL150829A0 (en) * 2002-07-21 2003-02-12 Yissum Res Dev Co Method and compositions for treatment of bone disorders
US20060269552A1 (en) * 2003-06-09 2006-11-30 Oron Yacoby-Zeevi Heparanase activity neutralizing anti-heparanase monclonal antibody and other anti-heparanase antibodies
EP1654380A4 (en) * 2003-08-14 2009-09-09 Insight Biopharmaceuticals Ltd METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING HEPARANASE ACTIVATION AND USES THEREOF
EP1670917A1 (en) * 2003-09-26 2006-06-21 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Synthetic heparanase molecules and uses thereof
WO2006120667A2 (en) * 2005-05-10 2006-11-16 Insight Biopharmaceuticals Ltd. Expression constructs and methods of using same for expressing heparanase in plants
US20080258890A1 (en) * 2006-05-22 2008-10-23 Todd Follmer System and Method for Remotely Deactivating a Vehicle
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3306316A1 (en) * 2016-10-10 2018-04-11 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Rep protein as protein antigen for use in diagnostic assays
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
KR927003090A (ko) * 1989-08-23 1992-12-17 하다사 메디칼 오르가니제이션 헤파린효소를 포함하는 상처 치유 약제
WO1995004158A1 (en) * 1993-07-29 1995-02-09 The Upjohn Company Use of heparanase to identify and isolate anti-heparanase compound
US5968822A (en) * 1997-09-02 1999-10-19 Pecker; Iris Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells
US6348344B1 (en) * 1997-09-02 2002-02-19 Insight Strategy & Marketing Ltd. Genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same
EP1032656A4 (en) * 1997-10-28 2002-10-29 Univ Australian ISOLATED NUCLEIC ACID MOLECULES, WHICH CODES FOR ENDOGLUCURONIDASE FROM MAMMALS, AND THEIR USE
GB9802725D0 (en) * 1998-02-09 1998-04-08 Ciba Geigy Ag Organic compounds

Also Published As

Publication number Publication date
US20030068806A1 (en) 2003-04-10
CA2329142A1 (en) 1999-11-11
WO1999057244A1 (en) 1999-11-11
US6475763B1 (en) 2002-11-05
EP1076689A1 (en) 2001-02-21
AU3770599A (en) 1999-11-23
AU768820B2 (en) 2004-01-08
US6348344B1 (en) 2002-02-19
US6426209B1 (en) 2002-07-30
NO20005100L (no) 2000-12-28
EP1076689A4 (en) 2003-04-02
JP2002513560A (ja) 2002-05-14

Similar Documents

Publication Publication Date Title
NO20005100L (no) Genetisk modifiserte celler og fremgangsmåter for ekspresjon av rekombinant heparanase og fremgangsmåter for rensing av samme
NO965365D0 (no) Hemmere av interleukin-1 omdannende enzym
NO973332D0 (no) Celler for fremstilling av rekombinante adenoviruser
FI965036L (fi) Interleukiini-beta:aa muuttavan entsyymin inhibiittoreita
NO955275D0 (no) Cellesvitsj og fremgangsmåte for ruting av celler derigjennom
FI970430L (fi) Atsa-asparaziinihappo analogeja 1-beta-interleukiinia muuttavan entsyymin inhibiittoreina
FI942624A0 (fi) Alfa-heteroaryylioksimetyyliketoneja interleukiini-1betaa muuttavan entsyymin inhibiittoreina
FI951579A7 (fi) Paneelimaisten osien liitosrakenne
PL353241A1 (pl) Mutanty enzymu transpozazy i sposób ich zastosowania
NO20003427D0 (no) Lomasse og fremgangsmÕte for dens fremstilling
FI942107L (fi) Peptidiketoneita interleukiini-1-betaa muuttavan entsyymin inhibiittoreina
NO991432L (no) Heterosykliske tioestere og ketoner
NO20000695D0 (no) Fiberstruktur og fremgangsmÕte for fremstilling derav
NO20014892L (no) Flertrinns elektromagnetisk separator for rensing av celler, kjemikalier og proteinstrukturer
ID23218A (id) Metoda pengobatan gagal jantung
DE59710130D1 (de) Verwendung verbindungsverfahrens und verbindungsverfahren
DK1011733T3 (da) Sammensætninger og fremgangsmåder til at forbedre levering af terapeutiske midler til celler
FI953186A7 (fi) Luusoluaktiviteetin arviointi
NO970086L (no) Heterocykliske azolonderivater med anti-Helicobacteraktivitet
NO963723D0 (no) Flytepunktsnedsettende tilsetningsstoffer og deres anvendelse
AU4607800A (en) Genetically modified plants tolerant of stress conditions
NO984132L (no) Enzymkombinasjoner for destruering av proliferative celler
NO995564D0 (no) Fremgangsmåte og konstruksjon for inhibisjon av cellemigrering
DK1032559T3 (da) Aminoalkylphenolderivater til behandling af depression og hukommelsessvigt
DE69936445D1 (de) Kristallines tnf-alpha-konvertierendes enzym und verwendung davon

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application